Viewing Study NCT06201234

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:34 AM
Ignite Modification Date: 2026-02-12 @ 7:03 AM
Study NCT ID: NCT06201234
Status: RECRUITING
Last Update Posted: 2025-12-01
First Post: 2023-12-07
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Sponsor: GBG Forschungs GmbH
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hormone Receptor Positive HER-2 Negative Breast Cancer View
None Advanced or Metastatic Breast Cancer View
None BRCA1 Mutation View
None BRCA2 Mutation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Elacestrant View
None Olaparib View
None Breast cancer View
None Metastases View
None Palliative therapy View